|
|
|
Saturday, March 7, 2009 — 7:00 PM, Convention Center 306
|
- Recent Advances in Thyroid Neoplasia
|
|
Moderators:
|
Vânia Nosé, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Ricardo V. Lloyd, Mayo Clinic, Rochester, MN
|
|
|
Disclosure:
|
In accordance with ACCME guidelines regarding disclosure, the USCAP policy requires that faculty members who have a significant financial or other relationship with a commercial company, entity, or service (which will be discussed in this Symposium) must disclose this to attendees. The Academy also requires that speakers disclose any products that are not labeled for the use under discussion. Virginia LiVolsi is a consultant for Veracyte. The other speakers listed below have indicated they have nothing to disclose.
|
Click the button above to add this event to your Itinerary Planner...
| 7:00 | Papillae, Nuclei, and Oncogenes: Back to the Drawing Board - Juan Rosai, Centro Diagnostico Italiano, Milan, Italy |
| 7:30 | Oncocytes, Oxyphils and Hürthle Cells - Sylvia Asa, University of Toronto, Toronto, Ontario |
| 8:00 | Tall Cell Papillary Thyroid Carcinoma - Virginia LiVolsi, University of Pennsylvania, Philadelphia, PA |
| 8:30 | Poorly Differentiated Carcinoma: From Morphology to Molecular Data and Return - Mauro Papotti, University of Turin, Torino, Italy |
|
Topics were chosen by an informal poll of members, a review of the programs from recent meetings, and consultations with current and past officers of the society, based upon the recent advances and difficulties in classification in selected well-differentiated and poorly-differentiated thyroid carcinomas. This symposium highlights problematic diagnostic areas in the diagnosis of papillary thyroid carcinoma, including tall cell variant (from the morphology to the new molecular aspects), the difficult diagnosis of oxyphilic thyroid tumors, and the new algorithmic diagnostic approach to poorly differentiated thyroid carcinoma. The objective of the program is to update general surgical pathologists to recognize important diagnostic, clinicopathologic, and molecular features in difficult thyroid tumors.
|
|
|
|
